Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | F10 | P00742 | 8/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172499 | 0.90 | F10 (0.35) | GPR119F10SMN1; SMN2MAPK14 | |
| SCHEMBL6170084 | 0.89 | GPR119 (0.36) | GPR119F10KIF18AMAPK14 | |
| SCHEMBL6169102 | 0.87 | F10 (0.39) | F10LMNA | |
| SCHEMBL6170090 | 0.85 | F10 (0.41) | F10 | |
| SCHEMBL6168757 | 0.84 | F10 (0.43) | F10 | |
| SCHEMBL6168830 | 0.82 | F10 (0.36) | GPR119F10KIF18AMAPK14TGFBR1 | |
| SCHEMBL6171243 | 0.79 | GPR119 (0.36) | GPR119F10SMN1; SMN2MAPK14 | |
| SCHEMBL6171172 | 0.77 | F10 (0.38) | GPR119F10LMNA | |
| SCHEMBL6169725 | 0.76 | F10 (0.39) | F10 | |
| SCHEMBL7082624 | 0.76 | F10 (0.45) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | GPR119 1388/4885F10 15/4885KIF18A 4553/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | GPR119 1388/4885F10 15/4885KIF18A 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.